Industry Trailblazers to Headline this Month’s CRISPR Summit
Add bookmark
[inlinead]CRISPR has attracted media attention this year charting potential patent disputes where fortunes could be at stake. Three key heavyweights said to be at the centre of these IP discussions are molecular biologists Jennifer Doudna, of University of Canada Berkeley, Emmanuelle Charpentierof the Max Planck Institute for Infection Biology and Feng Zhangof the Broad Institute and Massachusetts Institute of Technology.This month’s CRISPR Gene Editing Summit - powered by Pharma IQ - will featu...
